Effectiveness of COVID-19 Vaccination on Transmission: A Systematic Review

被引：12
作者：
Oordt-Speets, Anouk [1 ]
Spinardi, Julia [2 ]
Mendoza, Carlos [3 ]
Yang, Jingyan [4 ]
Morales, Graciela [5 ]
Mclaughlin, John M. [6 ]
Kyaw, Moe H. [6 ]
机构：
[1] Epi C Epidemiol Consultancy, NL-3846 AG Harderwijk, Netherlands
[2] Pfizer Inc, Vaccine Med Affairs, Emerging Mkts, BR-06696270 Itapevi, Brazil
[3] Pfizer Inc, Patient Hlth & Impact, Mexico City 05120, Mexico
[4] Pfizer Inc, Global Value & Access, New York, NY 10017 USA
[5] Pfizer Inc, Vaccine Med Affairs, Emerging Markets, New York, NY 10017 USA
[6] Pfizer Inc, Vaccine Sci Affairs, New York, NY 10017 USA
来源：
COVID | 2023年 / 3卷 / 10期
关键词：
SARS-CoV-2; COVID-19; vaccination; transmission; viral load; INFECTION;
D O I：
10.3390/covid3100103
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Vaccination against infectious disease affords direct protection from vaccine-induced immunity and additional indirect protection for unvaccinated persons. A systematic review was conducted to estimate the indirect effect of COVID-19 vaccination. From PubMed and Embase, 31 studies were included describing the impact of original wild-type COVID-19 vaccines on disease transmission or viral load. Overall, study results showed the effectiveness of COVID-19 vaccination against SARS-CoV-2 transmission (range 16-95%), regardless of vaccine type or number of doses. The effect was apparent, but less pronounced against omicron (range 24-95% for pre-omicron variants versus 16-31% for omicron). Results from viral load studies were supportive, showing SARS-CoV-2 infections in vaccinated individuals had higher Ct values, suggesting lower viral load, compared to infections among the unvaccinated. Based on these findings, well-timed vaccination programs may help reduce SARS-CoV-2 transmission-even in the omicron era. Whether better-matched vaccines can improve effectiveness against transmission in the omicron era needs further study.
引用
收藏
页码：1516 / 1527
页数：12
相关论文
共 57 条
  • [1] Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
    Abu-Raddad, Laith J.
    Chemaitelly, Hiam
    Ayoub, Houssein H.
    Tang, Patrick
    Coyle, Peter
    Hasan, Mohammad R.
    Yassine, Hadi M.
    Benslimane, Fatiha M.
    Al-Khatib, Hebah A.
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Shaik, Riyazuddin Mohammad
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed Ghaith
    Butt, Adeel A.
    Al-Romaihi, Hamad Eid
    Al-Khal, Abdullatif
    Al-Thani, Mohametabd H.
    Bertollini, Roberto
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [2] Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study
    Allen, Hester
    Vusirikala, Amoolya
    Flannagan, Joe
    Twohig, Katherine A.
    Zaidi, Asad
    Chudasama, Dimple
    Lamagni, Theresa
    Groves, Natalie
    Turner, Charlie
    Rawlinson, Christopher
    Lopez-Bernal, Jamie
    Harris, Ross
    Charlett, Andre
    Dabrera, Gavin
    Kall, Meaghan
    [J]. LANCET REGIONAL HEALTH-EUROPE, 2022, 12
  • [3] Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be Surrogates for Replication-Competent Virus
    Binnicker, Matthew J.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (11)
  • [4] Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021
    Braeye, Toon
    Cornelissen, Laura
    Catteau, Lucy
    Haarhuis, Freek
    Proesmans, Kristiaan
    De Ridder, Karin
    Djiena, Achille
    Mahieu, Romain
    De Leeuw, Frances
    Dreuw, Alex
    Hammami, Naima
    Quoilin, Sophie
    Van Oyen, Herman
    Wyndham-Thomas, Chloe
    Van Cauteren, Dieter
    [J]. VACCINE, 2021, 39 (39) : 5456 - 5460
  • [5] Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms
    Bramante, Carolyn T.
    Proper, Jennifer L.
    Boulware, David R.
    Karger, Amy B.
    Murray, Thomas
    Rao, Via
    Hagen, Aubrey
    Tignanelli, Christopher J.
    Puskarich, Michael
    Cohen, Ken
    Liebovitz, David M.
    Klatt, Nichole R.
    Broedlow, Courtney
    Hartman, Katrina M.
    Nicklas, Jacinda
    Ibrahim, Sherehan
    Zaman, Adnin
    Saveraid, Hanna
    Belani, Hrishikesh
    Ingraham, Nicholas
    Christensen, Grace
    Siegel, Lianne
    Sherwood, Nancy E.
    Fricton, Regina
    Lee, Sam
    Odde, David J.
    Buse, John B.
    Huling, Jared D.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (05):
  • [6] Cochrane Emergency Critical Care Group, 2023, Cochrane Database Syst. Rev, V12, pCD015477
  • [7] Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
    de Gier, Brechje
    Andeweg, Stijn
    Backer, Jantien A.
    Hahne, Susan J. M.
    van den Hof, Susan
    de Melker, Hester E.
    Knol, Mirjam J.
    [J]. EUROSURVEILLANCE, 2021, 26 (44)
  • [8] Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
    Eyre, David W.
    Taylor, Donald
    Purver, Mark
    Chapman, David
    Fowler, Tom
    Pouwels, Koen B.
    Walker, A. Sarah
    Peto, Tim E. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (08) : 744 - 756
  • [9] Indirect protection of children from SARS-CoV-2 infection through parental vaccination
    Hayek, Samah
    Shaham, Galit
    Ben-Shlomo, Yatir
    Kepten, Eldad
    Dagan, Noa
    Nevo, Daniel
    Lipsitch, Marc
    Reis, Ben Y.
    Balicer, Ran D.
    Barda, Noam
    [J]. SCIENCE, 2022, 375 (6585) : 1155 - +
  • [10] What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
    Hodgson, Susanne H.
    Mansatta, Kushal
    Mallett, Garry
    Harris, Victoria
    Emary, Katherine R. W.
    Pollard, Andrew J.
    [J]. LANCET INFECTIOUS DISEASES, 2021, 21 (02) : E26 - E35
123456